Screening and monitoring for infectious complications when immunosuppressive agents are studied in the treatment of autoimmune disorders

Journal of the Pediatric Infectious Diseases Society

Volumn 4, Issue 3, 2015, Pages 198-204

  Loechelt, Brett J ^a,e   Green, Michael ^b   Gottlieb, Peter A ^c   Blumberg, Emily ^d   Weinberg, Adriana ^c   Quinlan, Scott ^e   Baden, Lindsey R ^f  

^a CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e GEORGE WASHINGTON UNIVERSITY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Immunosuppressive agents; Infectious complications

Indexed keywords

ALPHA INTERFERON; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BODY PIERCING; CANNABIS USE; CYTOMEGALOVIRUS; DISEASE PREDISPOSITION; ENZYME LINKED IMMUNOSPOT ASSAY; EPSTEIN BARR VIRUS; HEPATITIS B VIRUS; HERPESVIRIDAE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTIOUS COMPLICATION; INSULIN DEPENDENT DIABETES MELLITUS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNEUMOCYSTIS JIROVECI; PRIORITY JOURNAL; SCREENING; SOCIAL STATUS; T LYMPHOCYTE; TATTOOING; TOXOPLASMOSIS; TUBERCULIN TEST; VIRUS LOAD; AUTOIMMUNE DISEASES; CLINICAL TRIAL (TOPIC); COMMUNICABLE DISEASES; COMPLICATION; IMMUNOCOMPROMISED PATIENT; OPPORTUNISTIC INFECTIONS; STANDARDS;

AUTOIMMUNE DISEASES; CLINICAL TRIALS AS TOPIC; COMMUNICABLE DISEASES; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; OPPORTUNISTIC INFECTIONS;

EID: 85006192541     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piu055     Document Type: Article

References (31)

1. Payne DC, Vinje J, Szilagyi PG, et al. Norovirus and medically attended gastroenteritis in U.S. children. N Engl J Med 2013; 368:1121-30.
2. Edwards KM, Zhu Y, Griffin MR, et al. Burden of human metapneumovirus infection in young children. N Eng J Med 2013; 368:633-43.
3. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Eng J Med 2009; 360:588-98.
4. Schwarzberg AB, Stover EH, Sengupta T, et al. Selective lymphopenia and opportunistic infections in neuroendocrine tumor patients receiving temozolomide. Cancer Invest 2007; 25:249-55.
5. Green M. Introduction: infections in solid organ transplantation. Am J Transplant 2013; 13(Suppl 4):3-8.
6. Issa NC, Marty FM, Gagne LS, et al. Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant 2011; 17:434-8.
7. Krause PJ, Gewurz BE, Hill D, et al. Persistent and relapsing babesiosis in immunocompromised patients. Clin Infect Dis 2008; 46:370-6.
8. Matsui T, Kang JH, Nojima M, et al. Reactivation of hepatitis B virus in patients with undetectable HBsAg undergoing chemotherapy for malignant lymphoma or multiple myeloma. J Med Virol 2013; 85:1900-6.
9. Oshima Y, Tsukamoto H, Tojo A. Association of hepatitis B with antirheumatic drugs: a case-control study. Mod Rheumatol 2013; 23:694-704.
10. Kim W, Kim SH, Huh SY, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol 2013; 20:975-80.
11. Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biological agents. Infect Dis Clin North Am 2010; 24:285-306.
12. Committee on Infectious Diseases, A.A.o.P. Red Book: 2012 Report of the Committee on Infectious Diseases. Pickering LK, ed. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012.
13. Hammond SP, Borchelt AM, Ukomadu C, et al. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009; 15:1049-59.
14. Emery VC, Hassan-Walker AF, Burroughs AK, Griffiths PD. Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and-experienced immunocompromised hosts. J Infect Dis 2002; 185:1723-8.
15. Paya CV. Prevention of cytomegalovirus disease in recipients of solid-organ transplants. Clin Infect Dis 2001; 32:596-603.
16. Weinberg A. The role of immune reconstitution in cytomegalovirus infection. BioDrugs 2002; 16:89-95.
17. Hammond SP, Martin ST, Roberts K, et al. Cytomegalovirus disease in lung transplantation: impact of recipient seropositivity and duration of antiviral prophylaxis. Transpl Infect Dis 2013; 15:163-70.
18. Evans AS, Niederman JC. Epstein-Barr virus. In: Evans AS, ed. Viral Infections of Humans: Epidemiology and Control. 3rd ed. New York: Plenum; 1991: p 265.
19. PayaCV, Fung JJ, NalenikMA, et al. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and the Mayo Clinic Organized International Development Meeting. Transplantation 1999; 68:1517-25.
20. Sanz J, Arango M, Senent L, et al. EBV-associated post-transplant lymphoproliferative disorder after umbilical cord blood transplantation in adults with hematological diseases. Bone Marrow Transplant 2014; 49:397-402.
21. Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007; 19:619-25.
22. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-608.
23. Loechelt BJ, Boulware D, Green M, et al. Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolate mofetil. Clin Infect Dis 2013; 56:248-54.
24. Vogl BA, Fagin U, Nerbas L, et al. Longitudinal analysis of frequency and reactivity of Epstein-Barr virus-specific T lymphocytes and their association with intermittent viral reactivation. J Med Virol 2012; 84:119-31.
25. Sousa H, Silva J, Azevedo L, et al. Epstein-Barr virus in healthy individuals from Portugal. Acta Med Port 2011; 24: 707-12.
26. Fiore AE, Shay DK, Broder K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008; 57(RR-7):1-60.
27. Thomas CF Jr, Limper AH. Pneumocystis pneumonia. N Engl J Med 2004; 350:2487-98.
28. Belatacept (BMS-224818) FDA's Cardiovascular and Renal Drugs Advisory Committee Briefing Document for March 2010 Meeting. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm201859.pdf. Accessed April 25, 2014.
29. Zarranz Imirizaldu JJ, Gomez Esteban JC, Rouco Axpe I, et al. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry 2003; 74: 1080-4.
30. Vikram HR, Dosanjh A, Blair JE. Coccidiodomycosis and lung transplantation. Transplantation 2011; 92:717-21.
31. Frank KM, Hogarth DK, Miller JL, et al. Investigation of the cause of death in a gene-therapy trial. N Engl J Med 2009; 361:161-9.